| Similar Articles |
|---|
 |
The Motley Fool
October 18, 2005
Brian Gorman |
PPD's Robust Pipeline The provider of drug development services continues to be a strong performer in its core business even as it demonstrates savvy in its new drug-partnering initiative. Investors, take note.   |
The Motley Fool
April 20, 2004
Brian Gorman |
PPD's New Possibilities The royalty stream from dapoxetine could significantly boost earnings. |
The Motley Fool
October 17, 2006
Brian Gorman |
PPD Disappoints? Not Quite Its discovery sciences business hindered results, but PPD remains a winner for investors. |
The Motley Fool
April 28, 2005
Brian Gorman |
PPD Branches Out The company, which concentrates on running clinical trials for pharmaceutical and biotech clients is right in diversifying, but its strategy carries its own risk. |
The Motley Fool
July 15, 2004
Brian Gorman |
Research Company's Stock Surges PPD's (formerly Pharmaceutical Product Development) second-quarter report isn't perfect, but long-term indicators look solid. The stock has risen as much as 14%. |
The Motley Fool
June 23, 2010
Brian Orelli |
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
Pharmaceutical Executive
December 1, 2010
Zhu Shen |
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda |
The Motley Fool
July 22, 2004
Brian Gorman |
Stability for Covance? After a solid quarter, the drug development service company may have found a way to keep revenue consistent. |
The Motley Fool
July 6, 2004
Brian Gorman |
Hidden Drug Costs Regulatory requirements play an important role in drug expenses. |
The Motley Fool
November 12, 2009
Brian Orelli |
How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way. |
The Motley Fool
November 1, 2005
Brian Gorman |
Kendle's Resurgence Can the contract pharmaceutical researcher continue its growth without more acquisitions? Despite the vibrant growth and its operational progress, Kendle still is at a disadvantage to larger rivals like Charles River Laboratories and PPD. |
The Motley Fool
October 3, 2011
Brian D. Pacampara |
Pharmaceutical Product Development Shares Soared: What You Need to Know Shares of Pharmaceutical Product Development skyrocketed 25% Monday after The Carlyle Group and Hellman & Friedman LP agreed to buy the health-care research specialist for $3.8 billion. |
The Motley Fool
October 29, 2009
Robert Steyer |
Pharma Researchers Need a Cure As the industry changes, Pharmaceutical Product Development and Parexel International struggle. |
